News
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Viking Therapeutics, Inc. (VKTX) closed at $28.19 in the latest trading session, marking a +1.7% move from the prior day.
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific ...
Casper, Wyoming Community News Stream.Voting for Oil City’s Best 2025 is NOW OPEN! We’re celebrating all the Stuff Locals Love! VOTE NOW for your favorite Casper-area people, places and things below!
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.52, representing a -5.86% change from its previous close.
Truist Financial analyst Joon Lee maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today. The company’s shares closed yesterday at $27.09. Confident Inv ...
Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...
Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...
Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results